Anteris Technologies Global Corp. ( (AVR) ) has released its Q2 earnings. Here is a breakdown of the information Anteris Technologies Global Corp. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Anteris Technologies Global Corp. is a global structural heart company focused on developing and commercializing innovative medical devices to restore healthy heart function, with a significant presence in Australia and the USA. In its latest earnings report for the second quarter of 2025, Anteris highlighted significant progress in its clinical development and strategic initiatives. The company reported that 130 patients have been implanted with its DurAVR® Transcatheter Heart Valve (THV) since the start of clinical development, with 21 patients treated in the second quarter alone. Notably, Anteris achieved a world-first ‘double DurAVR®’ implant, marking a significant milestone in its clinical advancements. The company is also preparing for the global PARADIGM Trial, having qualified 79 clinical sites and hosted global investigator meetings to align operational activities. Financially, Anteris reported net operating cash outflows of $41.0 million for the first half of 2025, reflecting increased clinical and manufacturing activities. The company held $28.4 million in cash and cash equivalents as of June 30, 2025. Looking ahead, Anteris remains focused on advancing its clinical and commercial objectives, supported by recent strategic board appointments and ongoing engagement with regulatory bodies.